Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
9,659.00
-11.00 (-0.11%)
At close: Dec 16, 2025
61.71%
Market Cap111.06B
Revenue (ttm)55.55B
Net Income (ttm)2.36B
Shares Outn/a
EPS (ttm)2.04
PE Ratio47.04
Forward PE11.46
Dividendn/a
Ex-Dividend Daten/a
Volume1,352,788
Average Volume1,468,279
Open9,638.00
Previous Close9,670.00
Day's Range9,599.00 - 9,824.00
52-Week Range4,865.00 - 9,824.00
Beta0.67
RSI78.64
Earnings DateJan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News

JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News

12 hours ago - GuruFocus

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

2 days ago - The Motley Fool

Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book

Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book

6 days ago - GuruFocus

Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings

Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings

6 days ago - GuruFocus

TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News

TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News

7 days ago - GuruFocus

TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News

TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News

7 days ago - GuruFocus

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.

7 days ago - Nasdaq

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

Share count rose by 868,457; position value increased by $71.98 million Post-trade stake: 16,692,680 shares valued at $337.19 million Holding now comprises 7.51% of fund AUM, making it the fund's 4th-...

7 days ago - The Motley Fool

Teva Pharmaceuticals Submits NDA For Olanzapine LAI

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the submission of a New Drug Application to the FDA for olanzapine extended-release injectab...

7 days ago - Nasdaq

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submis...

7 days ago - GlobeNewsWire

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.

7 days ago - Nasdaq

Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus

Whales with a lot of money to spend have taken a noticeably bullish stance on Teva Pharmaceutical Indus . Looking at options history for Teva Pharmaceutical Indus (NYSE: TEVA) we detected 9 trades. I...

8 days ago - Benzinga

Teva Pharmaceutical (TEVA) Receives a Boost in Price Target by Goldman Sachs | TEVA Stock News

Teva Pharmaceutical (TEVA) Receives a Boost in Price Target by Goldman Sachs | TEVA Stock News

8 days ago - GuruFocus

3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.

8 days ago - Nasdaq

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2025 Update

Duquesne Family Office's ~$4.06B 13F portfolio remains concentrated, with the top five holdings—Natera, Insmed, Teva Pharma, Taiwan Semi, and...

9 days ago - Seeking Alpha

Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions. Pfizer is stabilizing af...

10 days ago - 24/7 Wall street

Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News

Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News

11 days ago - GuruFocus

Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript

12 days ago - GuruFocus

Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story.

Israel's stock market has outpaced U.S. markets since Oct. 7, 2023, with U.S.-traded leaders like Teva, Elbit Systems and Tower Semiconductor showing big gains.

12 days ago - Investor's Business Daily

TEVA Forecasts Significant Rise in Cash Flow by 2030

TEVA Forecasts Significant Rise in Cash Flow by 2030

13 days ago - GuruFocus

Noteworthy ETF Inflows: IEFA, SPOT, SE, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an ap...

14 days ago - Nasdaq

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks

Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte...

16 days ago - The Motley Fool

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) short interest as a percent of float has risen 6.52% since its last report. According to exchange reported data, there are now 50.39 million shares s...

19 days ago - Benzinga